Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28242185 | 0.78 | HPGD (0.33) | ALDH1A1CYP3A4IDO1 | |
| SCHEMBL20670556 | 0.78 | TTR (0.39) | CA1CA2CA9 | |
| SCHEMBL2314837 | 0.78 | ALDH1A1 (0.40) | ALDH1A1CYP3A4 | |
| SCHEMBL2861514 | 0.77 | CYP3A4 (0.58) | ALDH1A1CYP3A4IDO1CA1CA2 | |
| SCHEMBL1570736 | 0.75 | CYP3A4 (0.36) | ALDH1A1CYP3A4CA1CA2CA9 | |
| SCHEMBL31180357 | 0.75 | CYP3A4 (0.36) | ALDH1A1CYP3A4CA1CA2CA9 | |
| SCHEMBL23301587 | 0.75 | GAA (0.36) | CYP3A4CA1CA2CA9 | |
| SCHEMBL20670791 | 0.75 | CA1 (0.32) | CA1CA2CA9 | |
| SCHEMBL12931055 | 0.75 | IDO1 (0.32) | IDO1 | |
| SCHEMBL29897454 | 0.75 | GAA (0.36) | CYP3A4CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3596069-B1 | KAPPA OPIOID RECEPTOR ANTAGONISTS AND PRODUCTS AND METHODS RELATED THERETO | SCRIPPS RESEARCH INST (US) | 2022-07-13 | — | — | EP | disclosed |
| US-20220162202-A1 | KAPPA OPIOID RECEPTOR ANTAGONISTS AND PRODUCTS AND METHODS RELATED THERETO | Neumora Therapeutics, Inc. | 2022-05-26 | — | — | US | disclosed |
| US-11124504-B2 | Kappa opioid receptor antagonists and products and methods related thereto | THE SCRIPPS RESEARCH INSTITUTE (US) | 2021-09-21 | — | — | US | disclosed |
| US-20210047310-A1 | KAPPA OPIOID RECEPTOR ANTAGONISTS AND PRODUCTS AND METHODS RELATED THERETO | Neumora Therapeutics, Inc. | 2021-02-18 | — | — | US | disclosed |
| US-10676469-B2 | Kappa opioid receptor antagonists and products and methods related thereto | BLACKTHORN THERAPEUTICS, INC. (US) | 2020-06-09 | — | — | US | disclosed |
| US-20190023700-A1 | KAPPA OPIOID RECEPTOR ANTAGONISTS AND PRODUCTS AND METHODS RELATED THERETO | Neumora Therapeutics, Inc. | 2019-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220162202-A1 | KAPPA OPIOID RECEPTOR ANTAGONISTS AND PRODUCTS AND METHODS RELATED THERETO | OPRK1, OPRD1, OPRM1 | ALDH1A1 2192/4885CYP3A4 856/4885IDO1 947/4885 |
| US-11124504-B2 | Kappa opioid receptor antagonists and products and methods related thereto | OPRK1, OPRD1, OPRM1 | ALDH1A1 2154/4885CYP3A4 843/4885IDO1 962/4885 |
| US-20190023700-A1 | KAPPA OPIOID RECEPTOR ANTAGONISTS AND PRODUCTS AND METHODS RELATED THERETO | OPRK1, OPRD1, OPRM1 | ALDH1A1 2154/4885CYP3A4 843/4885IDO1 962/4885 |
| US-10676469-B2 | Kappa opioid receptor antagonists and products and methods related thereto | OPRK1, OPRD1, OPRM1 | ALDH1A1 2154/4885CYP3A4 843/4885IDO1 962/4885 |
| US-20210047310-A1 | KAPPA OPIOID RECEPTOR ANTAGONISTS AND PRODUCTS AND METHODS RELATED THERETO | OPRK1, OPRD1, OPRM1 | ALDH1A1 2154/4885CYP3A4 843/4885IDO1 962/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.